EWPI BIG NEWS!
Post# of 321
EWPI BIG NEWS!! Approval From Food & Drugs Board
Emerging World Pharma Inc. Strategic Partner African Global Pharma Corp. Approval From Food & Drugs Board Ghana for Anti-Mala...
Emerging World Pharma Inc. (PINKSHEETS: EWPI) strategic partner African Global Pharma Corp. (AGP) has informed us that the Food and Drugs Board of Ghana approval of the anti-malarial pharmaceutical Gloderp® is in the final stages of the registration process with the company anticipating full approval before this quarter end. The Food and Drugs Board of Ghana is a Ghanaian government agency responsible for the inspection, certification and proper distribution of foods and food products and drugs in Ghana. There remains an ongoing demand for anti-malarial medicines in Ghana and surrounding African countries that is readily made available at affordable prices.
Upon approval African Global Pharma GH would be the only manufacturer of Golderp® in capsule form in Ghana. This would allow AGP to readily manufacture and distribute the anti-malarial medicine in an affordable and timely manner throughout Ghana and other West African countries. It will be produced in (AGP) Sunyani, Ghana manufacturing facility.
Gloderp® is used for the treatment of uncomplicated malaria caused by falciparum, vivax and or malariae. Each capsule will contain Dihydroartemisinin 40mg and Piperaquine Phosphate 320mg.
About African Global Pharma, Ghana
African Global Pharma (Ghana) Limited is an affiliated company of African Global Pharma Corp. of Canada with business partnership with the Catholic Diocese of Sunyani to distribute all our manufactured drugs to the Catholic Mission Hospitals. African Global Pharma's production facility in Sunyani, Ghana was fully rehabilitated and built by African Global Pharma Corp, Canada. The plant and its operations are headquartered in Sunyani at the Diocesan Bldg.
For more on AGP click here http://www.globalpharmacorp.ca/african-gp-ghana.html
About Emerging World Pharma Inc.
Emerging World Pharma Inc. is an investor in generic based pharmaceutical companies manufacturing within developing nations.
The company focuses its investments on generic pharmaceutical companies that have contracts with three major buyer groups; church, government and wholesalers. Market research shows that these branches are the most secure, protected and reputable for the distribution of medicines.
For more on Emerging World Pharma Inc. click here http://www.emergingpharma.com/